Genmab A/S (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have earned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $45.20.

Several equities analysts have weighed in on the company. Truist Financial dropped their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th. Redburn Atlantic began coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. Morgan Stanley reissued an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Genmab A/S in the first quarter valued at $43,000. Janney Montgomery Scott LLC raised its stake in Genmab A/S by 43.2% in the 1st quarter. Janney Montgomery Scott LLC now owns 17,369 shares of the company’s stock valued at $520,000 after acquiring an additional 5,238 shares during the period. Capstone Investment Advisors LLC purchased a new stake in Genmab A/S during the first quarter valued at about $655,000. Thompson Davis & CO. Inc. bought a new position in Genmab A/S during the first quarter worth about $202,000. Finally, Grandfield & Dodd LLC increased its stake in shares of Genmab A/S by 3.4% in the first quarter. Grandfield & Dodd LLC now owns 26,418 shares of the company’s stock worth $790,000 after purchasing an additional 860 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

GMAB opened at $22.78 on Thursday. Genmab A/S has a fifty-two week low of $22.22 and a fifty-two week high of $32.89. The firm has a market capitalization of $15.08 billion, a PE ratio of 18.83, a P/E/G ratio of 0.66 and a beta of 0.99. The company’s 50-day moving average is $24.78 and its 200 day moving average is $26.54.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, analysts expect that Genmab A/S will post 1.29 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.